INDICATIONS AND USAGE（适应症）

BLENREP is indicated for the treatment of adults with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).

DOSAGE（服用剂量）

Perform an ophthalmic exam prior to initiation of BLENREP and during treatment.

Advise patients to use preservative-free lubricant eye drops and avoid contact lenses unless directed by an ophthalmologist.

Recommended Dosage

The recommended dosage of BLENREP is 2.5 mg/kg of actual body weight given as an intravenous infusion over approximately 30 minutes once every 3 weeks until disease progression or unacceptable toxicity.

ADVERSE REACTIONS（不良反应）

Ocular toxicity

Thrombocytopenia

Infusion-related reactions

For full information, please refer to:

https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/16a160a4-3ec0-4ddf-99ce-05912dd3382d/spl-doc?hl=Blenrep

Blenrepinformation